Improving medication adherence with technology
The longstanding adherence problem is yielding to new technology
Real-World Evidence (RWE): Advancing Both Clinical and Commercial Objectives
The widening scope of RWE data available from patients is changing both clinical and post-approval practices for drug development
New science energizes the cancer market
An ‘overwhelming’ information load is affecting oncology’s ability to develop successful treatment pathways
Targeting the gatekeepers in long term care
The ‘age in place’ trend creates challenges for market access to seniors
Orphan drug commercialization is maturing
Existing incentives continue to draw in new drug developers; payers begin to look at competitive markets to drive down drug costs
Cardiovascular therapy: More new drugs for a growing patient base
The scale of the cardiovascular market pushes payers to demand quality outcomes data
Oncology: a new era in therapies; same cost concerns
A raft of new therapies is generating renewed optimism for cancer care, but even as lower-cost biosimilars enter the market, cost is a crippling factor